Midi Health Medical Leadership and Credentials: An Independent Review

What Is Midi Health and Who Runs Its Clinical Program?

Midi Health launched in 2021 with a stated mission of closing the care gap for women in midlife. The company's co-founders include Joanna Strober, a venture-backed entrepreneur, alongside a founding medical advisory group that includes OB/GYN physicians. The clinical model pairs patients with a dedicated care team rather than a single on-demand provider, which is a structural departure from platforms like Teladoc or Hims/Hers.

Founding Medical Advisory Structure

The company publicly lists its Chief Medical Officer and clinical advisors on its website, though those names and credentials should be verified directly at your state medical board before beginning care. Board certification status for physicians can be confirmed at the American Board of Medical Specialties (ABMS) [1]. Nurse practitioner credentials are verifiable through the American Association of Nurse Practitioners' license verification tool.

The Menopause Society Membership Claim

Midi Health claims that its providers include members of The Menopause Society (formerly the North American Menopause Society, NAMS). The Menopause Society's 2023 position statement on menopausal hormone therapy states that "for most healthy symptomatic women who are younger than 60 years or within 10 years of menopause onset, the benefits of MHT outweigh the risks" [2]. Providers trained within that framework are operating from current, guideline-concordant clinical knowledge. NAMS membership is a professional affiliation, not a board certification, so the two distinctions are worth keeping separate when you evaluate provider qualifications.

Is Midi Health Legitimate? Regulatory and Licensing Analysis

Short answer: Midi Health appears to operate as a legally registered telehealth entity, but independent credential verification by the patient remains the standard of care for any online prescriber.

Corporate Registration and State Licensing

Midi Health operates through professional corporations (PCs) registered in each state where it provides care, which is the standard legal structure for telehealth companies operating across state lines under the corporate practice of medicine doctrine. Patients in states with restrictive telehealth prescribing laws may see limited formulary access. The Federation of State Medical Boards (FSMB) maintains a public lookup for telehealth interstate compacts, and Midi Health's participating states are listed on its own website [3].

BBB and Consumer Complaint Profile

The Better Business Bureau (BBB) does not show Midi Health as an accredited business as of July 2025. A small number of informal reviews appear on the BBB profile, with complaints centered on billing delays and prior-authorization friction with insurance carriers rather than clinical safety concerns. The absence of accreditation is common among telehealth startups and does not constitute evidence of fraud, though BBB accreditation does add a layer of accountability that the company has not yet sought.

LegitScript Certification

LegitScript, the third-party pharmacy and telemedicine verification service, has not issued a published certification for Midi Health as of this review. LegitScript certification signals that a platform meets standards for prescription drug dispensing and practitioner legitimacy. Its absence does not mean the platform is unsafe, but patients and payers may use it as one data point [4].

FDA and DEA Compliance

Midi Health does not appear on the FDA's list of enforcement actions against healthcare entities [5]. The hormones most commonly prescribed on the platform (17-beta estradiol, micronized progesterone, and low-dose testosterone) are FDA-approved products dispensed through licensed pharmacies, including 503A compounding pharmacies for custom doses. The FDA's guidance on compounded hormone therapy is publicly available and outlines acceptable use cases [6].

Clinical Credentials of Midi Health Providers

Physician and Advanced Practice Provider Qualifications

Midi Health states that its providers are board-certified in OB/GYN, internal medicine, family medicine, or advanced women's health. Board certification through ABMS requires completion of an accredited residency, passage of written and oral examinations, and ongoing continuing medical education. Patients can verify any MD's or DO's board certification at no cost at the ABMS website [1].

Nurse practitioners (NPs) on the Midi platform hold either an FNP (Family Nurse Practitioner) or WHNP (Women's Health Nurse Practitioner) credential. The WHNP-BC credential, offered through the National Certification Corporation (NCC), requires graduate-level education and a proctored examination focused specifically on women's reproductive health across the lifespan [7]. NPs with WHNP-BC training are better positioned for menopause management than general FNPs, though both can legally prescribe HRT in most U.S. States.

Menopause-Specific Training

The Menopause Society offers a Menopause Practitioner (MSCP) certification for clinicians who complete a structured curriculum and pass a competency assessment. Midi Health has stated publicly that it prioritizes hiring providers with menopause-specific training or who are working toward MSCP status. Independently confirmed numbers are not publicly available, so patients should ask their assigned provider directly whether they hold MSCP certification.

Prescribing Protocols and Clinical Guidelines Adherence

Midi Health's stated prescribing approach aligns with three main guideline sources. The Menopause Society's 2023 position statement recommends transdermal estradiol as a first-line formulation for most patients due to lower thrombotic risk compared to oral estrogen [2]. The ACOG Practice Bulletin No. 141 supports individualized HRT decision-making for symptomatic menopausal women [8]. The Endocrine Society's 2015 guidelines for testosterone therapy in women recommend a careful risk-benefit analysis before prescribing, given limited long-term safety data [9].

A useful framework for evaluating any menopause telehealth provider against these guidelines is the following three-question checklist. First, does the provider assess cardiovascular risk before initiating estrogen, using validated tools such as the Framingham 10-year risk score? Second, does the provider distinguish between FDA-approved hormone products and custom-compounded formulations, explaining why a compounded product is being chosen? Third, does the provider schedule a follow-up visit within 8 to 12 weeks of initiating therapy, consistent with the Menopause Society's monitoring recommendation? Midi Health's care model includes scheduled follow-up visits, which meets that third criterion.

What Midi Health Prescribes: Formulary and Safety Standards

Hormone Therapy Options

The platform's formulary includes transdermal estradiol (patches, gels, sprays), oral micronized progesterone (Prometrium), vaginal estradiol (Vagifem, Yuvafem, Imvexxy), and low-dose testosterone (typically compounded). The availability of both FDA-approved products and 503A compounded options is a clinical strength, because some patients genuinely require doses or delivery systems not available in commercial products. Still, the FDA has noted that compounded hormones "are not FDA-approved and have not been evaluated for safety or efficacy" [6], a distinction Midi Health providers are obligated to communicate.

Non-Hormonal Prescribing

For patients who cannot or choose not to use hormones, Midi Health prescribers can initiate SSRIs such as paroxetine (the only FDA-approved non-hormonal menopause treatment for vasomotor symptoms, marketed as Brisdelle at 7.5 mg) [10], SNRIs such as venlafaxine, and gabapentin. In 2023, fezolinetant (Veozah) received FDA approval specifically for vasomotor symptoms in menopause at 45 mg daily [11]. Whether Midi Health's formulary includes fezolinetant should be confirmed during an initial visit.

Compounding Pharmacy Partnerships

Midi Health works with 503A compounding pharmacies for custom hormone preparations. The FDA regulates 503A compounders under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by licensed pharmacists [6]. Patients receiving compounded products should confirm that the pharmacy is state-licensed and operating under a valid prescription.

Patient Experience and Complaints: What the Data Show

Common Billing Complaints

The most frequently cited frustration in public reviews is billing transparency and insurance prior authorization. Midi Health accepts insurance, which is a genuine differentiator from cash-only platforms, but prior authorizations for hormones such as testosterone or brand-name estradiol patches can take one to three weeks. This is a payer-side issue rather than a Midi Health clinical failure, but patients entering the platform with urgent symptom burden should plan for a potential lag before medication is dispensed.

Clinical Satisfaction Data

Independent clinical satisfaction data for Midi Health is limited. The company has reported internally that a majority of users see symptom improvement within 90 days, though this figure has not been published in a peer-reviewed journal. For context, the REPLENISH trial (N=1,835) showed that a combined estradiol/progesterone oral capsule (Bijuva) reduced moderate-to-severe vasomotor symptoms by approximately 64% vs. 50% for placebo at 12 weeks [12]. Any competent menopause provider should be targeting similar response rates with appropriate therapy selection.

Scope-of-Practice Concerns

Some public reviews raise questions about whether NPs rather than physicians handle most patient interactions. NPs practicing at the top of their license with menopause-specific training can deliver care equivalent to physician care for most perimenopause and menopause presentations, a position supported by the American Association of Nurse Practitioners [13]. Complex cases involving premature ovarian insufficiency, surgical menopause, or breast cancer history should ideally involve MD/DO oversight, and patients in those situations should ask at enrollment whether physician supervision is built into their care pathway.

How Midi Health Compares to Menopause Society Standards

The Menopause Society's criteria for a "menopause-friendly" practice include individualized risk assessment, access to FDA-approved HRT formulations, provision of non-hormonal alternatives, and documented follow-up. Midi Health's published model addresses all four criteria on paper. Execution varies by individual provider, as it does in any practice.

The 10-Year Cardiovascular Risk Assessment

Before initiating systemic estrogen therapy, clinicians should assess cardiovascular risk. The American Heart Association's 2011 guideline on cardiovascular disease prevention in women explicitly cautions against using menopausal hormone therapy in women with established cardiovascular disease [14]. A provider who skips this assessment is not practicing within standard of care, regardless of platform.

Breast Cancer Risk Screening

The combination of estrogen and progestogen carries a small but statistically significant increase in breast cancer risk with prolonged use, a finding confirmed in the Women's Health Initiative (WHI) with a hazard ratio of 1.26 for combined HRT vs. Placebo after 5.6 years of follow-up (N=16,608) [15]. Any Midi Health provider initiating combined HRT should document a baseline breast cancer risk discussion, including Gail model score if appropriate.

Bone Health Considerations

Menopause accelerates bone loss. The National Osteoporosis Foundation recommends DEXA screening for all women 65 and older and for postmenopausal women under 65 with risk factors [16]. HRT has a bone-protective effect, but osteoporosis management sometimes requires additional agents such as bisphosphonates. Midi Health's scope appears to include ordering DEXA scans and interpreting results within a care plan, though patients should confirm this at enrollment.

Verified Red Flags to Watch for on Any Menopause Telehealth Platform

No single telehealth company is uniformly excellent across all providers. These are objective warning signs that apply to Midi Health and its competitors alike.

• A provider who initiates testosterone in a woman without first checking baseline total and free testosterone levels is not following Endocrine Society guidelines [9].
• Prescribing compounded "bioidentical" hormone pellets without informed consent documentation about the FDA's concerns is a documented problem across the telehealth sector [6].
• Failing to discuss endometrial cancer risk in women with a uterus who receive unopposed estrogen violates standard HRT prescribing protocol.
• Any platform refusing to share a provider's full name, license number, or state of licensure should be treated with caution.

Midi Health publishes provider profiles with names and credentials on its website. Patients can take those names to their state medical board's public lookup tool to confirm active licensure.

Original Clinical Assessment: HealthRX Medical Team Review

The HealthRX medical team reviewed Midi Health's publicly available clinical protocols, provider bios, and treatment documentation against current Menopause Society, ACOG, and Endocrine Society standards. Our assessment: the company's published clinical framework is guideline-concordant for the majority of uncomplicated perimenopause and menopause presentations. The primary areas where independent verification is warranted are (1) confirmation of individual provider MSCP status or equivalent menopause-specific training, (2) the compounding pharmacy chain of custody for custom testosterone preparations, and (3) how complex cases involving comorbidities are triaged to physician oversight. Patients should request and document their provider's full license number and board certification at first contact.